VIR Stock Overview
An immunology company, develops therapeutic products to treat and prevent serious infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vir Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.34 |
| 52 Week High | US$13.09 |
| 52 Week Low | US$6.56 |
| Beta | 0.49 |
| 1 Month Change | 3.09% |
| 3 Month Change | -3.42% |
| 1 Year Change | -27.40% |
| 3 Year Change | -82.42% |
| 5 Year Change | -40.66% |
| Change since IPO | -47.65% |
Recent News & Updates
Recent updates
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
Dec 13Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
Nov 05Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts
Nov 04
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
Sep 08Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results
Aug 03Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
Jul 17Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates
May 05Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
May 03Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Feb 28Sticking With Vir Biotechnology
Jan 17Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%
Aug 07Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive
Jul 24Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically
Feb 28Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 07Shareholder Returns
| VIR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.5% | -3.6% | -2.4% |
| 1Y | -27.4% | -2.6% | 23.4% |
Return vs Industry: VIR underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: VIR underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| VIR volatility | |
|---|---|
| VIR Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VIR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VIR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 587 | Marianne De Backer | www.vir.bio |
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Vir Biotechnology, Inc. Fundamentals Summary
| VIR fundamental statistics | |
|---|---|
| Market cap | US$1.01b |
| Earnings (TTM) | -US$533.34m |
| Revenue (TTM) | US$78.62m |
12.9x
P/S Ratio-1.9x
P/E RatioIs VIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIR income statement (TTM) | |
|---|---|
| Revenue | US$78.62m |
| Cost of Revenue | US$495.55m |
| Gross Profit | -US$416.93m |
| Other Expenses | US$116.41m |
| Earnings | -US$533.34m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.87 |
| Gross Margin | -530.33% |
| Net Profit Margin | -678.40% |
| Debt/Equity Ratio | 0% |
How did VIR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:01 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vir Biotechnology, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Huidong Wang | Barclays |
| Alec Stranahan | BofA Global Research |